Organprotektion Lab

From OpenWetWare

(Difference between revisions)
Jump to: navigation, search
(Publications)
Current revision (15:30, 26 January 2011) (view source)
(Members)
 
(4 intermediate revisions not shown.)
Line 7: Line 7:
However, infarct sparing therapies can often only be applied after the patient’s admission to the hospital. Even in this situation the patient can benefit from the application of volatile anesthetics.Recently, it has been described that volatile anesthetics also exert cardioprotective properties when administered after the ischemic injury (anesthetic-induced postconditioning, APOST). This might be of enormous therapeutical implications since myocardial ischemia is often unpredictable.<br>
However, infarct sparing therapies can often only be applied after the patient’s admission to the hospital. Even in this situation the patient can benefit from the application of volatile anesthetics.Recently, it has been described that volatile anesthetics also exert cardioprotective properties when administered after the ischemic injury (anesthetic-induced postconditioning, APOST). This might be of enormous therapeutical implications since myocardial ischemia is often unpredictable.<br>
-
The intracellular mechanisms underlying APC and APOST are under intense investigation. The projects performed by our group aim to identify triggers, mediators and end-effectors of anesthetic-induced pre- and postconditioning and to characterize their complex intracellular interaction. Given the large incidence of perioperative cardiovascular morbidity and mortality and the incidence of myocardial and cerebral infarction, the results of these projects are of high clinical relevance and might provide a better understanding of the cardioprotective properties of volatile anesthetics. They might help to choose the appropriate and protective anesthesiology regime to alleviate cardiovascular mortality and apoplectic insults in the perioperative period.<br>
+
The intracellular mechanisms underlying APC and APOST are under intense investigation. The projects performed by our group aim to identify triggers, mediators and end-effectors of anesthetic-induced pre- and postconditioning and to characterize their complex intracellular interaction. Particularly, we focuse on ß1- and ß2-adrenergic receptors and their downstream targets. Given the large incidence of perioperative cardiovascular morbidity and mortality and the incidence of myocardial and cerebral infarction, the results of these projects are of high clinical relevance and might provide a better understanding of the cardioprotective properties of volatile anesthetics. They might help to choose the appropriate and protective anaesthesia regime to alleviate cardiovascular mortality and apoplectic insults in the perioperative period.<br>
==Members==
==Members==
'''Head:'''
'''Head:'''
-
Dr. Markus Lange
+
PD Dr. Markus Lange
'''Research Fellows:'''
'''Research Fellows:'''
* Dr. Thorsten Smul
* Dr. Thorsten Smul
-
* Dr. [[Andreas Redel]]
+
* Dr. Christopher Lotz (currently at UC Los Angeles, USA)
-
* Dr. Christopher Lotz (currently at UC Los Angeles)
+
* Dr. [[Jan Stumpner]]
* Dr. [[Jan Stumpner]]
-
* Dr. Christoph Blomeyer
+
* Dr. Christoph Blomeyer (currently at Medical College of Wisconsin, Milwaukee, USA)
 +
* Tobias Tischer-Zeitz
 +
* Dr. Sonja Maisch
 +
* Anja Frank
-
'''Visiting Research Fellow'''
+
External Collaborator
-
* Dr. Feng Gao
+
* Dr. [[Andreas Redel]], [http://www.uniklinikum-regensburg.de/kliniken-institute/Anaesthesiologie/ Department of Anesthesiology], [http://www.uniklinikum-regensburg.de/ Hospital of the University of Regensburg]
'''MD Students:'''
'''MD Students:'''
Line 36: Line 38:
* Andreas Beck
* Andreas Beck
* Andreas Neuwirth
* Andreas Neuwirth
 +
* Julia Umminger
 +
* Ulrike Kolar
'''Technician:'''
'''Technician:'''

Current revision

Welcome to our OWW homepage! To get further information, please visit our lab homepage!

Our group in 2007
Our group in 2007

Contents

Anesthetic-induced preconditioning and postconditioning

Volatile anesthetics not only induce anesthesia, but also render organs resistant against ischemic damage. For example, the magnitude of an experimentally induced myocardial infarct size can be reduced by more than 50% by the administration of volatile anesthetics, even if the administration has been discontinued prior to the ischemic injury (anesthetic-induced preconditioning, APC). These protective effects are also effective in other organ systems; e.g. the brain. APC is as effective as ischemic preconditioning and thus represent one of the most potent therapeutic strategies of infarct size reduction. Surgery-related temporary ischemia of the heart or the brain can be prevented using APC in the perioperative period.

However, infarct sparing therapies can often only be applied after the patient’s admission to the hospital. Even in this situation the patient can benefit from the application of volatile anesthetics.Recently, it has been described that volatile anesthetics also exert cardioprotective properties when administered after the ischemic injury (anesthetic-induced postconditioning, APOST). This might be of enormous therapeutical implications since myocardial ischemia is often unpredictable.

The intracellular mechanisms underlying APC and APOST are under intense investigation. The projects performed by our group aim to identify triggers, mediators and end-effectors of anesthetic-induced pre- and postconditioning and to characterize their complex intracellular interaction. Particularly, we focuse on ß1- and ß2-adrenergic receptors and their downstream targets. Given the large incidence of perioperative cardiovascular morbidity and mortality and the incidence of myocardial and cerebral infarction, the results of these projects are of high clinical relevance and might provide a better understanding of the cardioprotective properties of volatile anesthetics. They might help to choose the appropriate and protective anaesthesia regime to alleviate cardiovascular mortality and apoplectic insults in the perioperative period.

Members

Head: PD Dr. Markus Lange

Research Fellows:

  • Dr. Thorsten Smul
  • Dr. Christopher Lotz (currently at UC Los Angeles, USA)
  • Dr. Jan Stumpner
  • Dr. Christoph Blomeyer (currently at Medical College of Wisconsin, Milwaukee, USA)
  • Tobias Tischer-Zeitz
  • Dr. Sonja Maisch
  • Anja Frank

External Collaborator

MD Students:

  • Tobias Nefzger
  • Tobias Tischer-Zeitz
  • Johannes Schmidt
  • Verena Schnupp
  • Anja Frank
  • Joanna Pociej
  • Anna Kellermann
  • Nadyia Virstyuk
  • Johannes Richl
  • Teresa Hilz
  • Andreas Beck
  • Andreas Neuwirth
  • Julia Umminger
  • Ulrike Kolar

Technician:

  • Katerina Pech

Methods

  • in vivo model of acute myocardial infarction in two rodent species
  • Western Blot
  • PCR
  • ELISA

Publications

  1. Stumpner J, Redel A, Kellermann A, Lotz CA, Blomeyer CA, Smul TM, Kehl F, Roewer N, and Lange M. . pmid:19934869. PubMed HubMed [Paper1]
  2. Redel A, Stumpner J, Tischer-Zeitz T, Lange M, Smul TM, Lotz C, Roewer N, and Kehl F. . pmid:19596824. PubMed HubMed [Paper2]
  3. Smul TM, Redel A, Stumpner J, Lange M, Lotz C, Roewer N, and Kehl F. . pmid:19467889. PubMed HubMed [Paper3]
  4. Lange M, Redel A, Smul TM, Lotz C, Nefzger T, Stumpner J, Blomeyer C, Gao F, Roewer N, and Kehl F. . pmid:19303329. PubMed HubMed [Paper4]
  5. Smul TM, Lange M, Redel A, Stumpner J, Lotz CA, Roewer N, and Kehl F. . pmid:19167913. PubMed HubMed [Paper5]
  6. Lange M, Redel A, Lotz C, Smul TM, Blomeyer C, Frank A, Stumpner J, Roewer N, and Kehl F. . pmid:19225392. PubMed HubMed [Paper6]
  7. Lange M, Smul TM, Redel A, Lotz C, Jazbutyte V, Schnupp V, Roewer N, and Kehl F. . pmid:18580175. PubMed HubMed [Paper7]
  8. Kranke P, Redel A, Schuster F, Muellenbach R, and Eberhart LH. . pmid:18518784. PubMed HubMed [Paper8]
  9. Redel A, Lange M, Jazbutyte V, Lotz C, Smul TM, Roewer N, and Kehl F. . pmid:18227289. PubMed HubMed [Paper9]
  10. Redel A, Jazbutyte V, Smul TM, Lange M, Eckle T, Eltzschig H, Roewer N, and Kehl F. . pmid:18156310. PubMed HubMed [Paper10]
  11. Muellenbach RM, Kredel M, Said HM, Klosterhalfen B, Zollhoefer B, Wunder C, Redel A, Schmidt M, Roewer N, and Brederlau J. . pmid:17563879. PubMed HubMed [Paper11]
  12. Lange M, Redel A, Roewer N, and Kehl F. . pmid:17457146. PubMed HubMed [Paper12]
  13. Lange M, Smul T, Zimmermann P, Kohlenberger R, Roewer N, and Kehl F. . pmid:17242104. PubMed HubMed [Paper13]
  14. Smul TM, Lange M, Redel A, Burkhard N, Roewer N, and Kehl F. . pmid:17006071. PubMed HubMed [Paper14]
  15. Lange M, Smul TM, Blomeyer CA, Redel A, Klotz KN, Roewer N, and Kehl F. . pmid:16931983. PubMed HubMed [Paper15]
  16. Eckle T, Grenz A, Köhler D, Redel A, Falk M, Rolauffs B, Osswald H, Kehl F, and Eltzschig HK. . pmid:16766632. PubMed HubMed [Paper16]
  17. Lange M, Roewer N, and Kehl F. . pmid:16399333. PubMed HubMed [Paper17]
  18. Golenhofen N, Redel A, Wawrousek EF, and Drenckhahn D. . pmid:16217658. PubMed HubMed [Paper18]
  19. Redel A, Baumgartner W, Golenhofen K, Drenckhahn D, and Golenhofen N. . pmid:12457251. PubMed HubMed [Paper19]
All Medline abstracts: PubMed HubMed

Links

Please visit our lab homepage!

Personal tools